definiens: means all types of financial, business, scientifi c, technical ( including but not limited to information concernin g ROR1 Antibody Products, the Products, biological materials, gene or protein sequences, Antibodies, a ntigens, cell lines, compounds, assays or test results ), economic or engineering information, including with out limitation, business strategies, business forecasts, product development plans, promotional a nd marketing objectives, results of operations, customer lists, supplier lists, patent disclosures, unpublished patent applications, know - how, trade secrets, compilations, ideas, inventions, discoveri es, techniques, methods, processes, procedures, formulae, designs, patterns, drawings, schematics, plans, configurations, specifications, data sheets, mock - ups, models, compounds, compositions, structur es, prototypes, clinical trial protocols, clinical data and analysis, formulae, software programs, sou rce documents, programs, code, materials, equipment, samples, test results, opinions, data, a nalysis and other proprietary information, whether tangible or intangible, and whether or how stored, compiled, or memorialized physically, electronicall y, graphically, photographically, or in writing, which is disclosed by one Party to the other Party hereunder or obtained by a Party through observatio n or examination of the other Party ’s facilities, information and/or materials ( such observation or e xamination hereinafter also referred to as for purposes of this Agreement ) . Notwi thstanding the foregoing, all Confidential Information related exclusively to a Product shall be deemed to be LICENSEE ’s Confidential Information ( and, for clarity, ( i ) Confidential Inf ormation existing as of the Effective Date exclusiv ely relating to a Product is being assigned to LICENSEE under this Agreement and LICENSEE shall be deemed the disclosing Party and LICENSOR shall be d eemed to be the receiving Party with respect thereto, and ( ii ) Section 8.3.1(b ) shall not apply to such Confidential Information ), and LICENSEE the disclosing Party, and LICENSOR the receiving Party, thereof regardless of the Party initially disclosi ng the same . For clarity, notwithstanding the foregoin g, all 22 Confidential Information related exclusively to a n aked ROR1 reactive Antibody disclosed by LICENSOR shall be LICENSOR ’s Confidential Informati on, and LICENSOR the disclosing Party, and LICENSEE the receiving Party, thereof